Q1 Earnings Forecast for Immatics Issued By Leerink Partnrs

Immatics (NASDAQ:IMTX - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Immatics in a report released on Thursday, March 27th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings of ($0.39) per share for the quarter. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics' Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS and Q4 2025 earnings at ($0.41) EPS.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%.

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $16.67.

Immatics Price Performance

Shares of IMTX traded down $0.33 during trading hours on Monday, hitting $3.84. 736,637 shares of the company were exchanged, compared to its average volume of 632,523. The firm has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $7.26. The company has a market capitalization of $458.33 million, a PE ratio of -5.82 and a beta of 0.83. Immatics has a one year low of $3.83 and a one year high of $13.77.

Institutional Trading of Immatics

Several large investors have recently added to or reduced their stakes in IMTX. The Manufacturers Life Insurance Company boosted its position in shares of Immatics by 9.3% in the third quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company's stock worth $1,880,000 after buying an additional 13,997 shares during the period. Wasatch Advisors LP increased its holdings in shares of Immatics by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 872,511 shares of the company's stock valued at $9,955,000 after purchasing an additional 29,239 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Immatics in the third quarter worth approximately $298,000. Quarry LP boosted its holdings in shares of Immatics by 29.4% during the third quarter. Quarry LP now owns 11,000 shares of the company's stock worth $126,000 after purchasing an additional 2,500 shares during the period. Finally, State Street Corp grew its position in Immatics by 11.2% during the third quarter. State Street Corp now owns 225,202 shares of the company's stock valued at $2,570,000 after purchasing an additional 22,710 shares in the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.